Search clinical trials for: Bivalent gp120/MF59® Placebo

Total 2274 results

National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

HIV Infections

United States, Zimbabwe, Tanzania, Zambia
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; HIV Vaccine Trials Network

Completed

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (HVTN107)

HIV Infections

South Africa, Mozambique, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...
Sanofi; GlaxoSmithKline; Bill and Melinda Gates Foundation

Completed

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
HIV Vaccine Trials Network
South Africa AIDS Vaccine Initiative

Completed

Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

HIV Seronegativity | HIV Preventive Vaccine

South Africa
National Institute of Allergy and Infectious Diseases...

Withdrawn

Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

HIV Infections | Pregnancy | HIV Seronegativity
Worcester HIV Vaccine
Brigham and Women's Hospital; Access to Advanced Health Institute (AAHI)

Completed

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

HIV Infections

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Icosavax, Inc.

Completed

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Healthy

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines and Diagnostics, Inc

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

HIV Infections

United States, South Africa
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Novartis Vaccines

Completed

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Influenza

United States, Colombia, Panama, Philippines
Novartis Pharmaceuticals

Completed

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Alzheimer's Disease

Belgium, Switzerland, Spain, United States, Italy, Sweden, Canada, Germany, Norway, Netherlands
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

HIV Infections

United States
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Completed

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants (HVTN 135)

HIV Infections

South Africa
International Vaccine Institute
Ministry of Health, Thailand

Enrolling by invitation

Effectiveness of Single Dose or Two Doses of Bivalent HPV Vaccine in Thailand (IVIHPV1)

Healthy

Thailand
Valenta Pharm JSC

Recruiting

Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections

Influenza, Human | Common Cold | Acute Respiratory Infection

Russian Federation
Novartis Vaccines

Completed

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

Influenza

Korea, Republic of
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel...

Completed

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

Healthy

United States
Robert Pass, MD
National Institute of Allergy and Infectious Diseases (NIAID); MCM Vaccines...

Completed

Recombinant CMV gB Vaccine in Postpartum Women

Cytomegalovirus Infections

United States
NPO Petrovax

Completed

Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus in Volunteers

Influenza

Russian Federation
MedImmune LLC

Completed

D2560C00015 FluMist Annual Safety Study 2018

Healthy | Influenza

United States
Shenzhen Shenxin Biotechnology Co., Ltd

Not yet recruiting

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Respiratory Syncytial Virus Infections
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Mahidol University; The Emmes... and other collaborators

Completed

HIV Vaccine Trial in Thai Adults

HIV Infection

Thailand
Janssen Vaccines & Prevention B.V.
Beth Israel Deaconess Medical Center; US Military HIV Research Program; Ragon...

Completed

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Human Immunodeficiency Virus

United States
Center for Disease Prevention and Control of Beijing...

Completed

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Mexico
National Institute of Allergy and Infectious Diseases...

Completed

Chiron Corp HCV E1/E2 Vaccine

Hepatitis C

United States
International AIDS Vaccine Initiative
Massachusetts General Hospital; GlaxoSmithKline; Fred Hutchinson Cancer Research... and other collaborators

Completed

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

HIV Infections

United States, Kenya
Sinovac Biotech Co., Ltd

Completed

The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

ALVAC-HIV vCP1452 Alone and Combined With MN rgp120

HIV Infections | HIV Seronegativity

Brazil, Peru, Haiti, Trinidad and Tobago
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

HIV Infections | HIV Seronegativity

United States
Emory University
Makerere University

Completed

Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda

Acquired Immunodeficiency Syndrome | HIV | Influenza

Uganda
Takeda

Completed

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

Norovirus Prevention

United States

3

Subscribe